VasoMedical to Showcase EECP® Therapy at 2013 Arab Health Exhibition
January 15, 2013 - WESTBURY, NY VasoMedical, Inc. (“VasoMedical”) (OTC BB:VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices for noninvasive cardiology including EECP® systems, the gold standard of ECP therapy, announced today that that the Company will attend and exhibit at the 2013 Arab Health Exhibition from January 28-31 in Dubai, United Arab Emirates.
The Arab Health Exhibition is the world's longest running healthcare exhibition and congress and the largest health conference in the Middle East. In previous years, this event has attracted more than 400 companies from across the globe, along with an audience of more than 80,000 medical professionals, distributors, dealers and suppliers from 142 countries. The exhibition itself features products and services on display from the world's leading manufacturers, wholesalers, and distributors.
VasoMedical will be located at Booth PZH25, located in Plaza Hall at the Dubai International Convention & Exhibition Centre. The Company will present its core technology, EECP® Therapy, as well as its BIOX ECG Holter, ambulatory blood pressure monitors and patient management products.
“The Arab Health Exhibition is a great opportunity to discover and share the latest developments in the healthcare sector, particularly in medical technology,” stated Larry Liebman, Vice President, Sales & Marketing for VasoMedical. “At VasoMedical, we welcome exposure to the medical and scientific communities from across the globe that aim to tackle the important health issues we face today.” Mr. Liebman continued, “Our presence at this exhibition allows us to showcase EECP® Therapy and the role it plays in treating cardiovascular diseases, which, as we all know, impacts people around the world. By raising awareness of the benefits of EECP® Therapy – from consistent improvement in patients' health to significant savings and reduced hospitalizations – we hope to educate conference attendees and increase acceptance of this non-invasive treatment, with the goal of widening the network of physicians who will use EECP®.”
The Middle East is one of the largest markets in the world for medical equipment and healthcare products; the region also serves as a scientific and educational platform for professionals in the healthcare industry.
VasoMedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company’s main proprietary products are EECP® Therapy systems, the gold standard of ECP treatment. The Company operates through three wholly owned subsidiaries: VasoSolutions, VasoMedical Global and VasoHealthcare. VasoSolutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems, and other medical equipment operations; VasoMedical Global operates the Company’s China-based subsidiaries; and VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments. Additional information is available on the Company's website at www.vasomedical.com.
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.